Stopping prednisone: which courses end on the last tablet, and which need 2.5 mg steps

Twelve days sits comfortably inside the window where stopping without a taper is the recommended approach. The 2024 joint guideline from the European Society of Endocrinology and the Endocrine Society suggests not tapering courses shorter than three to four weeks irrespective of the dose, and it goes further by advising against measuring cortisol in those patients, because sustained suppression of the hypothalamic-pituitary-adrenal axis is unlikely over that period. So the instruction you were given matches current guidance, and adding a taper would have meant more days on a drug that had finished its job. The feeling you describe has a name and it is not adrenal failure. Glucocorticoid withdrawal syndrome covers fatigue, aching muscles and joints, low appetite, flattened mood and broken sleep in someone whose adrenal function is adequate. It happens because the body spent a fortnight in a supraphysiological state and now has to readjust to its own 10 to 20 mg of cortisol a day. It follows even fairly short courses and it settles on its own, usually inside one to two weeks. What would change the picture is a different symptom set: dizziness on standing, vomiting you cannot stop, abdominal pain, weight loss, or feeling profoundly and disproportionately unwell during a second illness. Those point at the axis rather than at post-course malaise and they justify a same-day call rather than watchful waiting. The distinction is worth memorising because the two states overlap enough to fool people, and only one of them is dangerous. There is a small-print question I would put to you before signing this off entirely. British formulary guidance asks for a gradual withdrawal even after short courses in several situations: more than 40 mg of prednisolone daily for over a week, doses repeatedly taken in the evening, recent repeated courses, or a short course within a year of stopping long-term steroid treatment. Forty milligrams for twelve days brushes against the first of those, since it is above 40 mg only if the equivalence is read strictly and you were at that dose for longer than seven days. In practice most clinicians would not taper a single twelve-day course in an otherwise unexposed patient, but if you took the whole dose at night, or if this was your third steroid course of the year, the answer shifts and it is worth raising. The gout question is separate and more useful than the taper question. Repeated flares needing systemic steroids suggest the urate is not being brought under control, and each course adds to cumulative exposure for bone and for the axis even though each one individually is safe. If you have needed prednisone more than once in a year, the productive appointment is about urate-lowering treatment rather than about how the last course ended. Practically: keep a note of the dates and doses of every steroid course from the past twelve months where you can find it, because that history is what determines how the next prescription is written and whether you need cover for surgery. Do not keep the leftover tablets for the next flare and start them yourself. And if the fatigue has not lifted after a fortnight, that is worth a conversation rather than another week of waiting. One more thing about the way the course was taken, since it changes the answer retrospectively. If any of those twelve days involved a dose in the evening, or the daily amount split into a morning and a night portion, that alone is listed in British formulary guidance as a reason to consider gradual withdrawal even after a short course. Adrenal activity peaks between 2 and 8 am, and an evening dose suppresses ACTH release precisely when the axis should be busiest. Nobody mentions the timing when they describe a course, so it is worth checking against the label on the box before concluding that the short-course rule covered you cleanly. Background on how I review these pages is on my reviewer page, and the drug detail sits on the prednisone page.

It is, and the reason is worth understanding because it makes the wait tolerable. Everything above roughly 5 mg is a conversation about your disease: how fast can the dose fall without the polymyalgia coming back. Everything below it is a conversation about your adrenal glands, and they run on a much slower clock. Fourteen months of supraphysiological dosing has told your pituitary to stop releasing ACTH, and without that signal the adrenal cortex thins. Restarting it means the hypothalamus resuming its releasing factors, ACTH returning to a pulsatile pattern, and only then cortisol production picking up. That sequence takes weeks to months and no prescription shortens it. The specific regimen your GP has chosen is the one published in Australian Prescriber for patients treated for more than six months: reduce the daily prednisolone dose from 5 mg to cessation by 1 mg every month. It is a reasonable and mainstream choice with no trial evidence behind it. There are very few studies informing the rate of reduction in this phase, and the guideline authors say so openly. The schedule reflects physiological reasoning and case experience, which is why you will find neighbours on different plans and both being managed correctly. There is an alternative worth asking about if five months feels unmanageable. The joint endocrine guideline gives two acceptable options once you reach the physiologic dose: continue tapering gradually with clinical monitoring, or measure a morning serum cortisol and let the number decide. The sample is taken between 8 and 10 am, before your morning tablet. Above 300 nmol/L, the glucocorticoid can generally be stopped rather than dwindled. Between 150 and 300 the physiologic dose continues with a repeat in a few weeks. Below 150 you carry on and retest months later. For someone at fourteen months of exposure the odds of a high result today are modest, but the test costs little and it converts an open-ended wait into a decision with a date attached. Polymyalgia adds one complication to that logic. It is one of the conditions where 5 mg may still be doing therapeutic work rather than merely covering the axis, and the guideline explicitly notes that assessment for recovery only applies if the dose is not needed for control of the underlying disease. If your shoulders and hips have been quiet for months, that concern falls away. If stiffness creeps back at 4 mg, the answer is a pause rather than a push. Expect to feel worse for a week or so after each step and do not read that as failure. Withdrawal symptoms - aching, tiredness, low appetite, poor sleep - follow reductions and settle. If they are severe, the recommended response is to return to the last dose you tolerated and lengthen the whole schedule, not to abandon it. Symptoms that involve dizziness on standing, vomiting or collapse are a different matter and need urgent review. Two practical things. Ask for the reduction plan in writing with dates, because five months of monthly steps is easy to lose track of. And make sure you know your sick-day instructions, since a suppressed axis cannot answer a fever on its own. It is also worth knowing what the five months are buying, because framed as pure delay it feels punitive. Each month at a given dose is time for the hypothalamus to resume its releasing factors, for ACTH to return to a pulsatile rhythm, and for the adrenal cortex to rebuild the tissue it lost while unused. That sequence runs at its own speed regardless of how motivated the patient is. The alternative - a faster finish followed by an adrenal crisis during the next chest infection - is the outcome the schedule exists to prevent, and it is a hospital admission rather than an inconvenience. Fourteen months in, five months out is a proportionate exchange. The safety side of long-term treatment is covered in the safety briefing.

In most countries the 2.5 mg tablet exists as a licensed strength - the US range runs 1, 2.5, 5, 10, 20 and 50 mg - so the first move is to ask the pharmacist to order it rather than to improvise at the kitchen table. Supply gaps are common and usually resolve in a day or two. If the strength genuinely is not available in your market, splitting a scored 5 mg tablet is something prescribers do authorise, but it should be authorised rather than assumed, because the answer depends on the specific product. Two things go wrong with splitting. The first is accuracy. A scored tablet split with a proper cutter gives halves that are close enough for most purposes, while a tablet broken by hand or cut with a knife routinely produces a 60:40 division. At 20 mg that variation is irrelevant. At the bottom of a reduction, where you are trying to hold a steady 2.5 mg while the adrenal axis restarts, a swing between 2 and 3 mg on alternate days is less than ideal, though it is not dangerous. The second problem is formulation: delayed-release prednisone and any modified-release product must never be cut, because the coating is the mechanism. Plain immediate-release tablets are the only candidates. There is also a simple alternative your prescriber may prefer. Prednisone and prednisolone come as oral solutions - 5 mg per 5 mL, and a concentrate at 5 mg per mL - which make any dose from 1 mg upward straightforward. Liquids are the standard answer for children and they work perfectly well for adults finishing a long reduction. The 1 mg tablet is another option and is exactly what the published schedules assume for the final phase, where the recommended step for someone treated more than six months is 1 mg per month from 5 mg to zero. What I would not do is convert this into alternate-day dosing on your own. Taking 5 mg every other day is not the same exposure profile as 2.5 mg daily, and while alternate-day regimens do exist in steroid practice, they are a prescribing decision with their own indications rather than a workaround for a supply problem. The same applies to skipping a day here and there to stretch a pack. One detail about timing while you are sorting this out. A single daily dose should be taken in the morning, before 9 am, because adrenal activity peaks between 2 and 8 am and morning dosing suppresses the axis less than the same total spread across the day. Repeated evening dosing is listed in British guidance as an independent reason to need a gradual withdrawal, so if the supply problem has been tempting you to take tablets late, that is worth correcting first. Taking the dose with food, or with milk, reduces gastric irritation. Ring the prescribing practice rather than solving this alone. A one or two day gap at 2.5 mg is not an emergency and there is no need to panic-halve anything today; what matters is that the schedule resumes accurately rather than drifting. If splitting is authorised, a few mechanical details make it work better. Use a purpose-made tablet cutter rather than a knife, split only immediately before taking the dose rather than preparing a week in advance, since exposed tablet surfaces absorb moisture, and if the two halves are visibly unequal take them on consecutive days rather than discarding the smaller one. Keep the cut halves in the original container rather than loose in a pill organiser. And ask the pharmacist to note on your record that you are splitting, so that any future prescription is written for a strength that does not require it. General material on the drug is on the prednisone page.

It means your adrenal axis is partly awake and not yet reliable, which is exactly the situation the middle band was designed to describe. The guideline thresholds run like this: above 300 nmol/L, roughly 10 micrograms per decilitre, the glucocorticoid can generally be stopped; between 150 and 300, continue the physiologic dose and repeat in a few weeks; below 150, continue and repeat in a few months. At 210 you are in the intermediate zone, closer to the upper end than the lower, and the sensible reading is that recovery is under way and the retest in a few weeks may well answer the question. Two technical points determine whether the number is trustworthy. The sample has to be drawn between 8 and 10 am, before you take the morning tablet, because cortisol has a strong diurnal rhythm and an afternoon sample is uninterpretable against these cut-offs. And it must not be taken while you are on dexamethasone; patients on long-acting glucocorticoids are switched to prednisolone or hydrocortisone first. If either condition was breached, the result needs repeating rather than interpreting. The guideline is careful to say that the value should be read as a continuum, with higher numbers more indicative of recovery, rather than as a pass or fail line. That matters in both directions. A result of 310 does not certify that you would cope with a bout of pneumonia; a result of 210 does not mean the axis is dead. Notice also what is not recommended: routine dynamic testing, such as a short Synacthen test, is advised against as a standard step during tapering. It has its place in specific situations, but not as a reflex when a morning cortisol comes back in the middle band. What happens next in practical terms is that you stay at the physiologic dose - the equivalent of 4 to 6 mg of prednisone - rather than continuing to reduce, and the assay is repeated. Some clinicians will instead skip the retest and simply carry on with a slow clinical taper, since the guideline treats gradual reduction with symptom monitoring and cortisol testing as two acceptable routes to the same destination. Either approach is defensible. What would not be defensible is stopping the tablet on the strength of a 210. One timeline to know. If the axis has still not recovered after a year at the physiologic daily dose, the guideline asks for evaluation by an endocrinologist rather than another cycle of the same plan. The same applies to anyone who has already had an adrenal crisis. Eight months of exposure with a partial result at this stage is entirely ordinary and does not put you in that category yet. While you wait, the important work is not the blood test. It is having sick-day instructions you can actually follow: what to take if you develop a fever needing bed rest or antibiotics, what to do if you vomit a dose, and who to contact out of hours. An axis reading 210 nmol/L on a good morning is an axis that will not cope with a bad week without help. Two questions are worth putting to whoever ordered the test. First, whether the assay used at your laboratory reports in the same units and against the same reference intervals as the guideline thresholds, since cut-offs quoted in nmol/L translate to roughly 10 micrograms per decilitre at the upper mark and different immunoassays are not perfectly interchangeable. Second, when the repeat is planned. A retest with no date attached tends to drift into next year, and the middle band is precisely where a scheduled repeat changes management. If you are also taking any drug that alters cortisol-binding globulin, oral oestrogen being the common one, mention it, because it shifts total cortisol measurements without reflecting the free hormone your tissues actually see.

The individual courses are all inside the short-course exemption, and none of them on its own warranted a taper. Taken together they land you in a different category, and it is one British formulary guidance names explicitly: gradual withdrawal should be considered in patients who have recently received repeated courses, particularly any lasting longer than three weeks, and in anyone taking a short course within a year of stopping long-term therapy. Twenty days of steroid spread across a year in four bursts is not the same as twenty consecutive days, but the axis responds to cumulative exposure more faithfully than the prescribing record suggests, and each course lands on the recovery from the last one. Whether that adds up to meaningful suppression depends on the spacing. Four courses evenly distributed across twelve months, with months of nothing in between, is a low-risk pattern. Four courses in a single winter, a fortnight apart, behaves far more like continuous therapy and would make me think about it differently. The dose matters too: 40 mg daily for more than a week is one of the listed triggers for a written withdrawal even in short treatment, so if any of those courses ran at high dose for longer than seven days, that one deserves attention on its own. The more important issue is upstream of all of it. Four rescue courses in a year is a marker of inadequately controlled asthma, and it is treated as such in respiratory practice. Two or more courses of oral corticosteroid in twelve months is one of the standard triggers for reassessing inhaled therapy, checking technique and adherence, and considering referral. The steroid courses are the symptom being measured, and the productive appointment addresses why the preventer plan is not holding rather than how each burst ends. Cumulative exposure also matters for reasons that have nothing to do with the axis. Repeated short courses accumulate towards bone loss and the other dose-dependent harms, and the thresholds involved are lower than most people expect - the American College of Rheumatology sets its fracture assessment trigger at 2.5 mg a day for more than three months. Intermittent bursts are not the same exposure, but they are not free either, and the running total belongs in your notes. That side of the ledger is covered in the safety briefing. Practically, three things. Write down the date, dose and length of every course including the ones you have already had, since nobody else is keeping that total. Mention the pattern before any surgery or general anaesthetic in the next twelve months, because the anaesthetic team asks about current medication and often misses a course that ended in spring. And if you notice that recovery after each course is taking longer than it used to, or that you feel unusually flattened between them, say so - that is the sort of observation that changes a management plan rather than a footnote to it. There is a further wrinkle specific to asthma that catches people out. Inhaled corticosteroids count towards total glucocorticoid exposure, particularly at high inhaled doses and particularly when combined with oral bursts, and UK guidance on identifying patients at risk of adrenal insufficiency lists inhaled steroids, nasal sprays, eye drops, topical preparations and injections alongside oral courses when totting up exposure across routes. Somebody on a high-dose inhaled preparation year-round plus four oral bursts has a larger cumulative figure than the oral prescriptions suggest. The same guidance flags ongoing glucocorticoid treatment alongside potent CYP3A4 inhibitors - some antifungals, some protease inhibitors, long-term clarithromycin - as an additional risk, because those drugs raise steroid exposure without any change in dose. Worth mentioning if you have been on a long antibiotic course.

You go up, and this is one of the few situations in steroid practice where the instruction is unambiguous. At 4 mg after a long course your adrenal axis cannot produce the extra cortisol a febrile illness demands, and the whole purpose of sick-day dosing is to supply what the glands cannot. The prednisone label states the principle in general terms: patients on corticosteroid therapy exposed to unusual stress require increased doses of a rapidly acting corticosteroid before, during and after the stressful situation. NICE guidance on adrenal insufficiency supplies the figures - during significant physiological stress, at least 40 mg of oral hydrocortisone daily in two to four divided doses, or at least 10 mg of oral prednisolone daily in one or two doses, until the acute illness resolves. The Society for Endocrinology puts it more simply for illness with fever that requires bed rest or antibiotics: double the usual daily oral dose. The reduction schedule pauses while this is happening. You do not continue stepping down during an acute illness, and you do not try to make up lost ground afterwards by taking a bigger step. The schedule resumes from where it stopped once you are well, typically after a few days at the normal dose, and losing a week matters far less than the alternative. The failure point to watch is vomiting. Oral dosing only works if the tablet stays down. If you are sick within 30 minutes of taking a dose, the dose is repeated once the vomiting settles, at double the original amount. If that comes back up too, or if you develop signs of adrenal crisis, you need intramuscular hydrocortisone and an emergency department, not another attempt at a tablet. Prolonged vomiting or diarrhoea is the standard indication to switch from oral to injected glucocorticoid, and influenza with gastrointestinal symptoms is exactly the scenario where people come unstuck at home. Know the picture you are guarding against. Adrenal crisis presents with postural dizziness, profound weakness, nausea, vomiting, abdominal pain and low blood pressure, and it is treated with 100 mg of hydrocortisone by immediate injection, followed by 200 mg over 24 hours and rapid rehydration - a litre of isotonic saline within the first hour. The reason to know the treatment is not so you can administer it, but so you recognise that this is a hospital event and call for help early rather than waiting to see whether the afternoon improves. Contact your prescribing practice today rather than tomorrow, both to confirm the increased dose and because influenza in someone on long-term steroids may warrant antiviral treatment and a lower threshold for assessing chest symptoms. Immunosuppression from glucocorticoids blunts the usual signs of a secondary bacterial infection, which is another reason not to manage this entirely by yourself. Ask, while you have them on the phone, for written sick-day instructions in milligrams of the tablets you actually hold - the generic advice to double up is much easier to follow when it names a number. A few things make the next few days safer. Keep fluids going, since dehydration does most of the damage in these situations and a suppressed axis handles it poorly. Make sure somebody at home knows you are on steroids and knows what adrenal crisis looks like, because the person who deteriorates is rarely the person who recognises it. Have a spare supply of tablets, since running out mid-illness is a common and avoidable route to trouble. And do not resume the reduction on the originally printed date simply because the date has arrived - resume it when you are genuinely well, which for influenza is usually a week or more after the fever settles. Anyone treating you in the next fortnight should be told the current dose and the fact that it has been increased for illness.

Both positions are defensible, which is an unsatisfying answer but an honest one. The argument for switching is mechanical: hydrocortisone has a shorter duration of biological action than prednisolone, so an evening trough is deeper and the axis gets more overnight room to attempt its own ACTH pulses. Several authors recommend it for exactly that reason. The argument against is that the supporting evidence is limited, and a recent study reported that most patients wean off prednisolone successfully without the switch. Australian Prescriber sets both sides out in the same paragraph rather than picking one, which tells you how settled the question is. Where a switch genuinely is recommended is a different scenario, and it is worth separating from yours. Patients on long-acting glucocorticoids - dexamethasone or betamethasone - should be moved to a shorter-acting agent such as hydrocortisone or prednisone once the long-acting drug is no longer needed. That is a specific guideline recommendation, and it has a practical corollary: a morning cortisol cannot be interpreted while a patient is taking dexamethasone, so the switch has to happen before any assessment of recovery. If you are already on prednisolone, neither of those reasons applies to you. The practical cost of switching is not zero. Hydrocortisone is taken in two or three divided doses rather than one, which most patients find more intrusive, and the reduction arithmetic changes: below 20 mg a day, a comparable regimen reduces the daily hydrocortisone dose by about 4 mg a month, against 1 mg a month for prednisolone from 5 mg. There is also a conversion step where errors happen. Against that, dividing the dose gives some people a smoother day and fewer withdrawal aches. My own view, for what it is worth in a general article, is that the switch is a reasonable option rather than a requirement, and that it earns its place mainly in patients who are struggling with withdrawal symptoms at low prednisolone doses or who have already spent a long time stuck at the physiologic dose without evidence of recovery. For a straightforward reduction that is progressing, adding a conversion introduces complexity for a benefit nobody has demonstrated. The decision belongs to whoever is writing your prescription, and disagreement between two clinicians is best resolved by putting the question to them directly rather than by choosing a side. What I would ask for either way is the same thing: a written plan with the current drug and dose, the next reduction and its earliest date, what to do if symptoms appear, and sick-day doses expressed in the tablets you actually have. That document matters more than which of the two glucocorticoids is named on it. If the discussion does go in favour of switching, ask three specific questions. What the conversion dose is, since hydrocortisone equivalence to prednisolone is roughly four to one and errors here are the main hazard of the manoeuvre. How the daily amount is divided, because hydrocortisone is normally given in two or three doses with the largest in the morning to imitate the natural rhythm. And what the reduction schedule becomes afterwards, since the arithmetic changes from 1 mg of prednisolone a month to roughly 4 mg of hydrocortisone a month below 20 mg daily. Sick-day instructions have to be rewritten at the same time, in the units of whichever tablet you end up holding, otherwise you finish the appointment with a new drug and an emergency plan written for the old one. That last point is the one most often missed. For what it is worth, the disagreement you have run into is not a sign that one of your clinicians is out of date. It reflects a genuine gap in the evidence, and the guideline text acknowledges it rather than resolving it. When two competent people differ on a point the literature has not settled, the sensible tiebreaker is whichever of them is going to manage the rest of the reduction and be available when something goes wrong. My background is on the reviewer page.

Alternate-day dosing is a real technique with a real rationale, and it is also one of the most frequently misapplied ideas in steroid practice. The logic is that a day without the drug lets the hypothalamic-pituitary-adrenal axis attempt its own rhythm, so suppression is less profound than with the same total dose given daily. British formulary guidance recognises the principle, and long-term alternate-day treatment with short-acting preparations is one of the situations in which vaccination guidance does not treat a patient as significantly immunosuppressed. So the underlying pharmacology is sound. The problems are practical. Alternate-day regimens do not suit every disease: some conditions flare reliably on the off day, which is why the technique is standard in a few settings and absent in others. They are also awkward to reduce from, because you end up manipulating two variables at once. And they are a prescribing decision rather than a patient adjustment, since converting a daily dose into an alternate-day one is not a like-for-like exchange and the correct conversion depends on why you are taking the drug in the first place. What I would not do is adopt this as a way of finishing a reduction faster. The published schedules for the final phase move in small daily decrements - 2.5 mg steps every two weeks between 10 and 5 mg, then roughly 1 mg a month below 5 mg for anyone treated longer than six months - and the slowness is the point. The axis recovers on its own timetable. Substituting a home-designed alternate-day plan for a prescribed daily one usually means less steroid than intended on some days and more on others, and both of those have costs. There is a version of your question with a much better answer, which is about timing rather than frequency. A single daily dose taken in the morning, before 9 am, suppresses the axis measurably less than the same total split across the day, because endogenous adrenal activity peaks between 2 and 8 am. Repeated evening dosing appears in British guidance as an independent reason a patient needs a gradual withdrawal at all. If any part of your dose is currently taken at night, moving it to the morning is a change with a clear rationale and no downside beyond a few nights of adjustment - and it is a change your prescriber will almost certainly agree to. Raise the alternate-day idea at your next appointment by all means, particularly if you are on a long maintenance dose rather than a reduction. Ask specifically whether your condition tolerates it and how the conversion would be done. What matters is that the change is prescribed and documented, so that anyone treating you in an emergency knows what you actually take on which day. Two consequences of alternate-day dosing are worth thinking through before you ask for it. The first is that sick-day instructions become more confusing, since an illness starting on an off day needs a clear rule about what to take and when, and confusion at that moment is exactly what the instructions exist to prevent. The second is that some people feel noticeably worse on the off day - aching, flat, unrefreshed - which is a mild version of the withdrawal picture and is one of the reasons the approach suits some patients and not others. Neither is a reason to reject the idea. Both are reasons to have it prescribed properly and reviewed after a month rather than adopted quietly at home and discovered later. The short answer to your original question, then, is that alternate-day dosing can reduce the degree of suppression while treatment continues, but it is not a recovery accelerator for someone finishing a course, and it is not something to adopt unilaterally. The two changes actually within your control are taking the whole dose in the morning and keeping an accurate record of what you take. Both are worth more than the theoretical gain you were hoping for. The safety picture for long-term dosing is covered in the safety briefing.